Refractory Cancer: Clinical Trials

1 trial for Refractory Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 recruiting. 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 41Recruiting 1

Follow Refractory Cancer: new trials by email Literature Review of Refractory Cancer trials Research Report on Refractory Cancer

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Plan Development for Giving Teclistamab in the Outpatient Setting
Teclistamab, Tocilizumab - Multiple Myeloma, Relapsed Cancer
Phase 4RecruitingUniversity Health Network, Toronto152024-11-192025-12-10

Narrower conditions

Multiple Myeloma (1)  ·  Neoplasms (1)  ·  Recurrence (1)

Broader conditions

Blood Protein Disorders (1)  ·  Cardiovascular Diseases (1)  ·  Disease Attributes (1)  ·  Hematologic Diseases (1)  ·  Hemic and Lymphatic Diseases (1)  ·  Hemorrhagic Disorders (1)  ·  Hemostatic Disorders (1)  ·  Immune System Diseases (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphoproliferative Disorders (1)  ·  Neoplasms by Histologic Type (1)  ·  Neoplasms, Plasma Cell (1)  ·  Paraproteinemias (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

tocilizumab (1)

Sponsors

University Health Network, Toronto (1)

Countries

Canada (1)

Top investigators

Christine Chen, Dr. (1)